AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
AngioDynamics, Inc.NASDAQ: ANGO
Selling, General & Admin · Q3 FY2026 · quarter ended Feb 2026
Selling, general & admin grows in line with its trailing trend
Q3 FY2026 selling, general & admin of $38.16M rose 6.0% year over year, in line with the +6.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Selling, general & admin amounted to 49.7% of revenue in FY2025, up 2.3 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $145.11M (-0.1%) for the fiscal year ending May 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterFeb 2026
- $38.16M+3.5% QoQ
- Last fiscal yearMay 2025
- $145.23M+0.9% YoY
- LTMFeb 2026
- $152.38M+6.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 145.23M USD
- Year-over-year change
- +0.9%
- 4-year CAGR
- +5.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | 145.23M | +0.9% |
| FY2024 | 2024-05-31 | 143.98M | -0.2% |
| FY2023 | 2023-05-31 | 144.25M | +7.9% |
| FY2022 | 2022-05-31 | 133.75M | +14.1% |
| FY2021 | 2021-05-31 | 117.22M | — |
Selling, General & Admin vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's LTM Feb 2026 selling, general & admin of $152.38M is the 8th highest of the 9 companies compared; the peer median is $718.87M.
- Its year-over-year change of +6.1% is the 5th highest of 9, against a peer median of +7.3%.
- Selling, general & admin amounts to 48.6% of revenue for ANGO, versus a peer median of 37.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $7.16B | +10.4% | +15.1% | 34.1% | |
| LTM Sep 2026 | $5.17B | -2.1% | +1.7% | 25.6% | |
| LTM Jun 2026 | $943.66M | +0.4% | -5.9% | 36.3% | |
| LTM Jun 2026 | $741.31M | +23.3% | +13.8% | 49.3% | |
| LTM Mar 2026 | $696.44M | -4.9% | +4.3% | 42.3% | |
| LTM Mar 2026 | $522.58M | +4.9% | +5.2% | 38.1% | |
| LTM Sep 2026 | $481.78M | +9.7% | +9.9% | 29.9% | |
| LTM Feb 2026 | $152.38M | +6.1% | +2.8% | 48.6% | |
| LTM Mar 2026 | $98.35M | +13.1% | +16.1% | 38.4% | |
| Peer median (excluding ANGO) | $718.87M | +7.3% | +7.6% | 37.2% | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 291.01M | 316.22M | 338.75M | 303.91M | 292.5M |
| Cost of Revenue | 134.22M | 150.49M | 164.51M | 149.22M | 134.79M |
| Gross Profit | 156.79M | 165.73M | 174.25M | 154.7M | 157.71M |
| Gross Margin | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% |
| Research & Development | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M |
| Selling, General & Admin | 117.22M | 133.75M | 144.25M | 143.98M | 145.23M |
| Operating Expenses | 192.07M | 194.2M | 225.43M | 347.13M | 197.66M |
| Depreciation & Amortization | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M |
| EBITDA | (9.28M) | 11.13M | 12.19M | (6.13M) | 1.74M |
| EBITDA Margin | -3.2% | 3.5% | 3.6% | -2.0% | 0.6% |
| Operating Income | (35.28M) | (28.47M) | (51.18M) | (192.44M) | (39.95M) |
| Operating Margin | -12.1% | -9.0% | -15.1% | -63.3% | -13.7% |
| Interest Income | 0 | 0 | 0 | 1.61M | 978K |
| Interest Expense | 861K | 688K | 2.7M | 0 | 0 |
| Other Income / Expenses | (769K) | (1.48M) | (3.26M) | 797K | 5.92M |
| Income Before Tax | (36.05M) | (29.95M) | (54.44M) | (191.64M) | (34.03M) |
| Pre-Tax Margin | -12.4% | -9.5% | -16.1% | -63.1% | -11.6% |
| Income Tax Expense | (4.5M) | (3.4M) | (2M) | (7.29M) | (39K) |
| Net Income | (31.55M) | (26.55M) | (52.44M) | (184.35M) | (33.99M) |
| Net Margin | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% |
| EPS (Basic) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| EPS (Diluted) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| Weighted Avg Shares | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
| Weighted Avg Shares (Diluted) | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.